The combined company will operate under the “Nuburu, Inc.” name and its common stock and warrants will commence trading on February 1, 2023

Suresh Pisharody brings strong leadership experience honed at Illumina, Thermo Fisher Scientific, and Guardant Health to lead BioSkryb in its next phase of growth

Yves Saw brings 30 years of experience in R&D, software and battery systems to South 8 

These funds will be used to grow MedCrypt’s engineering team in response to an increased demand for encryption and PKI solutions optimized for medical devices

New appointments aid in goal of ensuring domestic supply chain of battery materials 

Jonathan Rowntree brings extensive experience in technical advanced materials and commercialization to advance Niron’s scaling and operational capabilities

New form factor accelerates high brightness integration in industrial fabrication machines

The 2023 Global Cleantech 100 recognizes e-Zinc as one of the exceptional innovators enabling the race to net-zero

The $3.125 million grant allows South 8 to develop high-power, rapid-charge Li-ion battery cells using its LiGas® electrolyte.

Innovative Materials meets High Precision Micro-Manufacturing, Accelerating the Development of Healthcare and Life Sciences Business 

Erwin Estigarribia appointed as Chief Executive Officer and Laura Beggrow appointed as Chief Commercial Officer

InterVenn’s senior management will present at the J.P. Morgan 41st annual Healthcare Conference on January 11, 2023

At 272 x 451 pixels, the module is one of the highest-resolution color MIP reflective LCDs of its size

Tailwind’s shareholders voted to approve the previously announced business combination between Tailwind and NUBURU as well as other proposals related to the business combination.

Following years of research and development at Princeton University, EnCharge AI emerges from stealth led by a world-class, multi-disciplinary team from Meta, NVIDIA, Qualcomm, and IBM.

Government funding and commercial partnerships further validate the potential of Niron’s Clean Earth Magnet® technology and will accelerate production plans to usher in a more sustainable future

South 8 Technologies welcomes intellectual property expert Andrew Filler to its board of directors.

Expansion adds a pilot production line for South 8’s unique liquefied gas electrolyte, marketed as LiGas®, for lithium-ion battery manufacturers and end-users seeking safer, higher performance and lower-cost battery-making materials.

InterVenn Biosciences announced Company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 17, 2022 at 2:30 p.m. Eastern Time.

New funding will allow Codetta and NCCU to advance COVID related research and future clinical care

Xendee’s integrated platform provides a standardized approach that cuts microgrid design time, slashes engineering expenses, and is scalable across the Department of Defense.

MedCrypt will use the funds for the continued delivery of proactive cybersecurity solutions to help medical device manufacturers meet cybersecurity requirements set by the FDA and international regulators

For the second consecutive year, Inc. recognized Anzu Partners for its commitment to breakthrough technology founders and entrepreneurs

The company’s technology enables the front facing camera and other sensors to be integrated under the display, eliminating notches and cut-outs in mobile devices screens

InterVenn is focusing on the development and commercialization of its Advanced Adenoma and Colorectal Cancer screening platform to change the paradigm for the detection of early-stage disease

AM Batteries (AMB) is a Boston-based innovative manufacturing company developing a next-generation, lower-carbon footprint and lower cost dry-electrode manufacturing technology for lithium-ion batteries

Xendee platform now offers tools to apply these incentives directly to the technologies during the modeling process.

Webinar will focus on the unmet medical need in HIV, therapeutic applications of gene delivery and editing for treatment of viral disease, and the Company’s ongoing Phase 1/2 trial evaluating the CRISPR-based therapy, EBT-101, as a treatment for HIV

The new plant will demonstrate the ability to domestically produce multiple battery chemistries in the same
factory with the capacity of 3,000 tons per annum (tpa) in 2025 scaling to 10,000 tpa in 2026

New partnership brings transformative, high-resolution single-cell genomic technology to the field of preimplantation genetic testing in the pursuit of improved discovery and clinical outcomes.

The funding will be used to expand production at e-Zinc’s new Mississauga, ON facility and accelerate commercialization efforts

e-Zinc announced that its CEO James Larsen was named one of Canada’s 2023 Clean50 in the research and development category.

InterVenn Biosciences announced that its co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in chemistry.

InterVenn Biosciences announced the appointment of Jason Myers, Ph.D., and Carol Berry to the company’s Board of Directors.

CIRM Grant of $6.85 million supports the first-in-human clinical study evaluating the safety and efficacy of EBT-101 in participants people living with HIV

The integration maximizes the efficiency of downloading past building load data directly from the utility, which gives engineers a more accurate view of past usage and peak requirements of their project.

Experts in materials science, engineering, and operations will help Niron commercialize the world’s first high performance rare-earth free permanent magnets

Rosenberg will work with portfolio companies as they develop their intellectual property strategies and more broadly support the next generation of transformative technology companies.

This new partnership brings high-resolution, single-cell whole genome and whole transcriptome analysis to Europe. This partnership will enable novel insights and deep cellular characterization required in the evaluation, creation, and validation of new generation biologics and therapeutics in targeted disease management.

GelSight Mini enables an enhanced AI-enabled tactile experience for users in just five minutes out of the box.

ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T-cell therapeutics announced that it has raised $14M in new financing.

Xendee’s optimization software even takes into account cable length, losses through transferring energy, and the most efficient ways to generate and distribute energy from multiple energy sources at all hours of the day.

Excision BioTherapeutics announced that the first participant has been dosed in the Phase 1/2 clinical trial of EBT-101 for human immunodeficiency virus type 1 (HIV-1).

ImmunoScape announced that Dan MacLeod, Ph.D., the company’s vice president of discovery, will present at the 7th Annual CAR-TCR Summit taking place September 19-22, 2022 in Boston.

Growth investment accelerates product innovation, talent acquisition and expansion in commercial, educational markets

Excision BioTherapeutics Inc. announced that Excision Management will present at the following upcoming investor conferences.

6K Additive produced from its UniMelt® plasma technology, announces a strategic AM powder supply agreement and recycling partnership with Freeville, NY-based Incodema3D.

An open-access Battery Intelligence platform to analyze batteries, build models and algorithms, collaborate and share insights

Aldo Carrascoso, Co-Founder and CEO, and Erwin Estigarribia, COO, will present at the 20th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2022 in New York, NY

Seasoned CFO joins NTx with deep global experience in building financial systems for startups, venture capital, and investor relations